Introduction {#sec1-1}
============

The sickle cell disorders are one of the major genetic and public health challenges in India.\[[@ref1], [@ref2]\] Anemia is a major morbidity among people with sickle cell disease. Anemia in pregnancy is an important cause of maternal complications, maternal and fetal morbidity and mortality in almost all the developing countries of the world including India.\[[@ref3], [@ref4]\] Patients suffering from sickle cell disease are generally anemic and are susceptible to infections that cause aggravation and severe clinical manifestations leading to early death. Affected infants with sickle cell disease may present with dactylitis, fever and overwhelming sepsis, chronic hemolytic anemia, jaundice, episodic vaso-occlusive crises, hyposplenism, periodic splenic sequestration (which can be life threatening in a small child) and bone marrow sepsis.\[[@ref5]-[@ref7]\] Inadequate availability of oxygen to fetus also leads to abortion, miscarriage or stillbirth. Genetically vulnerable groups include: infants, growing children, adolescents, pregnant women and a large number of ignorant people. Inherited disorders of hemoglobin cause high degree of hemolytic anemia, clinical jaundice, frequent infections, painful crises, splenomegaly, etc. and are responsible for the high infant morbidity, mortality and fetal loss in populations of under developed and developing tropical countries of the world.\[[@ref8], [@ref9]\]

The purpose of this study was to screen and identify the couples with and without sickle cell disorders and to compare their reproductive outcomes with regards to abortions, miscarriages or stillbirths, neonatal mortality, infant mortality, and childhood mortality. The goal is to investigate whether carrier couples of sickle cell disorders independently contribute more towards reproductive loss as a result of hemolytic anemia in the families and consequently to the population than the couples without these disorders. It also investigated whether the identified difference are due to confounding non-dependable variables such as birth asphyxia, pre-eclamptic toxemia, puerperal sepsis, prematurity, low birth-weight babies, maternal malnutrition, serious malarial or other urino-genital tract infections, diarrhea, immunological incompatibility (such as ABO and Rhesus blood groups) between mother and fetus (HDN), congenital anomalies or hereditary hemolytic disorders such as glucose-6-phosphate dehydrogenase (G6PD) deficiency, and physical injuries during intrauterine period/delivery. Keeping the non-dependable confounding variables almost similar, being taken from the same source for both these groups, the difference in two groups, if any amounts to reproductive outcome of the sickle cell disorders specifically of the homozygous sickle cell disease.

Madhya Pradesh state is predominantly poor, prevalent low-birth-weight babies with undernourishment and anemia, poor child feeding practices, food insecurity, vulnerability to infectious environment, limited access to basic health care services, and overwhelming neonatal/infant mortality. The early identification and intervention of infants with sickle cell disease has shown markedly reduced morbidity and mortality elsewhere.\[[@ref3]\] The present study will be of immense interest to the global health community because along with the screening and identification of infants with sickle cell disorders, the exploration of reproductive outcome in carrier couples of sickle cell disease has also been investigated. This study is among the first to explore the reproductive loss due to sickle cell disorders in terms of abortions, miscarriages or stillbirths, neonatal mortality, infant mortality, and childhood mortality in the vulnerable couples from central India where a huge population is afflicted with sickle cell disease disability.\[[@ref10], [@ref11]\]

Methods {#sec1-2}
=======

A total of 383 suspected couples including their offspring with at least one suspected/confirmed case of anemia/sickle cell disorders routinely referred by the experts (in Gynecology, Pediatrics, and Blood Bank) for investigations/confirmation of diagnosis, attending Netaji Subhash Chandra Bose Medical College & Hospital, Jabalpur, Madhya Pradesh in Central India were included in the study. Ethical clearance was obtained from the Human Ethical Committee of Regional Medical Research Centre for Tribals, Jabalpur, India.

Confirmed carrier couples of sickle cell disorders formed our study group and the negatives (normal and without sickle cell disorders), free of

hematological disorders/anemia, after rigorous scrutiny, were taken as controls. Cases suffering from other hemoglobinopathies and genetic abnormalities and with iron deficiency anemia, hematological disorders, malaria, accidental or induced abortion (dependable variables) were excluded from the study. All the non-genetic confounding factors more or less were similar for both groups (matched case controls), being taken from the same population source. Detailed reproductive history of each couple was recorded retrospectively like total number of conceptions, abortions, miscarriages or still-births, live-births, surviving children, neonatal or infant deaths, etc. [Table 1](#T1){ref-type="table"} provides a breakdown of the couples investigated in the study. Out of 383 couples investigated, 200 were found normal and 183 couples had different sickle cell disorders. A total of 1397 persons (703 males and 694 females) were investigated for sickle cell disorders including the controls.

###### 

Distribution and genotypes of couples with and without different sickle cell disorders

  No. of Couples (N)   Genotypes of Couples (Diagnosis)             Interpretation of Genotypes
  -------------------- -------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  65                   AA/AS                                        Normal husband and sickle cell trait wife or normal wife and sickle cell trait husband
  18                   AA/SS                                        Normal husband and sickle cell disease wife or vice versa
  72                   AS/AS                                        Both husband and wife are carrier for sickle cell disease
  9                    AS/SS                                        One partner is carrier for sickle cell disease and other partner is suffering from sickle cell disease
  15                   AS/β-Thalassemia Trait                       One partner being carrier for sickle cell disease and the counterpart is β-thalassemia trait (or carrier of thalassemia major)
  4                    AS/Sickle cell- β-Thalassemia                One partner being carrier of sickle cell disease and the other partner is sickle cell-β-thalassemia (having compound disease, i.e. sickle cell disease and β-thalassemia)
  183                  Sickle Cell Disorders (All above combined)   All the above diagnostic categories (genotypes) combined together except the normal controls
  200                  AA/AA (Normal)                               Normal husband and normal wife (control)

Intravenous 2-3ml blood was taken under aseptical conditions from each individual after taking informed/written consent for screening of sickle cell disorders. Hematological parameters were studied using an automated Blood Cell Counter (Model-MS~5~9, Melet Schloesing Laboratories, Cergy-Pontoise Cedex, France). Sickling test was performed using 2% freshly prepared sodium meta-bisulphite solution as reducing agent for the presence or absence of sickle cell hemoglobin.\[[@ref12]\] The routine hemoglobin (Hb) lysate electrophoresis was carried out on cellulose acetate membrane (CAM) in Tris-EDTA-Borate buffer at pH 8.6 and quantification of A~2~ fraction of adult hemoglobin was done by elution method.\[[@ref12], [@ref13]\] The value of more than 3.5% of A~2~ fraction of adult hemoglobin was taken as cut off point for determining the β-thalassemia trait. Estimation of fetal hemoglobin was done as described by Weatherall.\[[@ref13]\]

The diagnosis of sickle cell-β-thalassemia was based on the findings of hemoglobin A, F, S and A~2~ on electrophoresis under alkaline pH, elevated (\>3.5%) A~2~ levels.\[[@ref2]\] All the doubtful cases were further subjected to hemoglobin variant analysis for detection of any discrepancy (Bio-Rad Diagnostics, Hercules California, USA). Data results were given to parents for treatment and further clinical management by the concerned referring doctor. All the carrier/affected persons were given genetic/marriage counseling.

Results {#sec1-3}
=======

Conceptions {#sec2-1}
-----------

It was observed that the average number of conceptions per couple was higher in different sickle cell disorders \[AS/AS (3.153); AA/AS (2.000), AA/SS (1.667); AS/SS (1.778); AS/β-thal (3.333); AS/S-β-thal (2.250); and β-thal/S-β-thal (2.250)\] than in normal controls (1.480).

Abortions {#sec2-2}
---------

Carrier couples of sickle cell disease ([Table 2](#T2){ref-type="table"}) had more abortions (7.0%) than in the controls (4%). Similar results were available for couples of AA/AS and AA/SS genotypes. The frequency of abortions was lower in AS/sickle cell-β-thalassemia (0.0%) and AS/SS (0.0%) couples than in the normal (4%) controls ([Table 2](#T2){ref-type="table"}). The number of abortions per 1000 live-births was almost doubled in carrier couples of sickle cell disease (78.4), followed by AA/AS (90.1) and AA/SS couples (142.8) than in normal controls (44.1) ([Table 3](#T3){ref-type="table"}).

###### 

Comparison of reproductive history of carrier couples with and without different sickle cell disorders

    Genotypes of Couples (Diagnosis)           No. of Couples N   Total No. of Conceptions   No. of Livebirths   No. of Abortions                        No. of Stillbirths   No. of Neonatal Deaths [●](#t2f5){ref-type="table-fn"}   No. of \<1 Year Deaths [◾](#t2f6){ref-type="table-fn"}   No. of \<10 Year Deaths                 No. of Surviving Offspring                                                                                                                                           
  -------------------------------------------- ------------------ -------------------------- ------------------- --------------------------------------- -------------------- -------------------------------------------------------- -------------------------------------------------------- --------------------------------------- ---------------------------- --------------------------------------- ---- --------------------------------------- ---- --------------------------------------- ----- ---------------------------------------
  AA/AS                                        65                 130                        111                 85.4^[a](#t2f1){ref-type="table-fn"}^   10                   7.7                                                      9                                                        6.9                                     4                            3.1                                     4    3.1                                     6    4.6                                     105   80.8^[d](#t2f4){ref-type="table-fn"}^
  AA/SS                                        18                 30                         21                  70.0^[b](#t2f2){ref-type="table-fn"}^   3                    10                                                       6                                                        20.0^[d](#t2f4){ref-type="table-fn"}^   1                            3.3                                     1    3.3                                     1    3.3                                     20    66.7^[d](#t2f4){ref-type="table-fn"}^
  AS/AS                                        72                 227                        204                 89.9                                    16                   7                                                        7                                                        3.1                                     7                            3.1                                     9    4                                       25   11.0^[d](#t2f4){ref-type="table-fn"}^   179   78.8^[c](#t2f3){ref-type="table-fn"}^
  AS/SS                                        9                  16                         14                  87.5                                    0                    0.0                                                      1                                                        6.2                                     3                            18.7^[d](#t2f4){ref-type="table-fn"}^   3    18.7^[d](#t2f4){ref-type="table-fn"}^   3    18.7^[d](#t2f4){ref-type="table-fn"}^   11    68.7^[b](#t2f2){ref-type="table-fn"}^
  AS/β-Thal.Trait                              15                 50                         49                  98.0                                    1                    2.0                                                      0                                                        0.0                                     1                            2.0                                     2    4.0                                     4    8.0                                     45    90.0
  AS/S-β-Thalassemia                           4                  9                          8                   88.9                                    0                    0.0                                                      1                                                        11.1                                    1                            11.1^[a](#t2f1){ref-type="table-fn"}^   1    11.1^[a](#t2f1){ref-type="table-fn"}^   1    11.1                                    7     77.8
  Sickle Cell Disorders (combined above all)   183                462                        407                 88.1                                    30                   6.5                                                      24                                                       5.2                                     17                           3.7                                     20   4.3^[a](#t2f1){ref-type="table-fn"}^    40   8.6^[d](#t2f4){ref-type="table-fn"}^    367   79.4^[d](#t2f4){ref-type="table-fn"}^
  AA/AA (Normal)                               200                296                        272                 91.9                                    12                   4.0                                                      11                                                       3.7                                     4                            1.3                                     4    1.3                                     8    2.7                                     264   89.2

Difference between diagnostic categories and normal controls is statistically significant at:

=p\<0.05;

=p\<0.02;

=p\<0.01;

=p\<0.001 level.

Birth to 28 days (Neonatal Mortality).

Birth to 365 days or within 1 year (Infant Mortality).

N= Number of couples; n= Number of observations; AA = Normal Adult Hemoglobin; AS = Sickle Cell Trait; SS = Sickle Cell Disease; β-Thal.Trait = Beta-Thalassemia Trait; S-β-Thal. = Sickle Cell-β-Thalassemia.

###### 

Comparison of reproductive history (figures are 1000 live-births) of carrier couples with and without different sickle cell disorders

   Genotypes of Couples (Diagnosis)            No. of Couples   No. of Conceptions   No. of Livebirths   No. of Abortions   No. of Stillbirths   No. of Neonatal Deaths [●](#t3f1){ref-type="table-fn"}   \< 1 Year Deaths [◾](#t3f2){ref-type="table-fn"}   \< 10 Year Deaths   Surviving Offspring
  -------------------------------------------- ---------------- -------------------- ------------------- ------------------ -------------------- -------------------------------------------------------- -------------------------------------------------- ------------------- ---------------------
  AA/AS                                        65               130                  111                 90.1               81.1                 36.0                                                     36.0                                               54.0                945.9
  AA/SS                                        18               30                   21                  142.8              285.7                47.6                                                     47.6                                               47.6                952.4
  AS/AS                                        72               227                  204                 78.4               34.3                 34.3                                                     44.1                                               122.5               877.4
  AS/SS                                        9                16                   14                  0.0                71.4                 214.3                                                    214.3                                              214.3               785.7
  AS/β-Thal.Trait                              15               50                   49                  20.4               0.0                  20.4                                                     40.8                                               81.6                918.4
  AS/S-β-Thal.                                 4                9                    8                   0.0                125.0                125.0                                                    125.0                                              125.0               875.0
  Sickle Cell Disorders (combined above all)   183              462                  407                 37.7               59                   41.8                                                     49.1                                               98.3                901.7
  AA/AA (Normal)                               200              296                  272                 44.1               40.4                 14.7                                                     14.7                                               29.4                970.6

Sickle cell disorders.

Birth to 28 days (Neonatal Mortality).

Birth to 365 days or within 1 year (Infant Mortality).

Still Births {#sec2-3}
------------

Couples of AA/SS genotypes had significantly (p\<0.001) higher number of still-births (20.0%) than the controls (3.7%). Almost similar results were obtained in couples of carriers of sickle cell disease and AS/S-β-thalassemia ([Table 2](#T2){ref-type="table"}). How-ever, the number of still-births per 1000 live-births was higher in couples of sickle cell disorders, AS/SS, AA/AS, AS/S-β-thalassemia, and AA/SS than the controls (40.4) ([Table 3](#T3){ref-type="table"}).

Neonatal Deaths {#sec2-4}
---------------

The number of neonatal deaths was significantly higher in couples of AS/sickle cell-β-thalassemia (p\<0.05) and also significantly higher in AS/SS couples (p\<0.001) compared to controls ([Table 2](#T2){ref-type="table"}). However, overall couples of sickle cell disorders were not significantly (\>0.05p\<0.10) different from the normal couples with respect to neonatal mortality. Neonatal deaths in carrier couples of sickle cell disorders constituted 85% of the infant deaths and 42% of the \<10 years deaths ([Table 2](#T2){ref-type="table"}). Neonatal mortality per 1000 live-births was almost doubled in carriers of sickle cell disease (34.3), and higher in couples of AS/β-thalassemia trait, AA/AS, AA/SS, AS/S-β-thalassemia, and AS/SS than in controls (14.7) ([Table 3](#T3){ref-type="table"}).

Infant Mortality {#sec2-5}
----------------

Couples of sickle cell disorders as a whole and AS/sickle cell-β-thalassemia showed significantly (p\<0.05) higher infant mortality and still higher in AS/SS couples (p\<0.001) than in the controls ([Table 2](#T2){ref-type="table"}). However, the carrier couples of sickle cell disease did not show significant (\<0.10p\>0.05) difference from normal controls for infant mortality. Infant mortality contributed 50% of \<10 year deaths in carrier couples of sickle cell disorders ([Table 2](#T2){ref-type="table"}). Infant mortality per 1000 live-births was three-folds higher ([Table 3](#T3){ref-type="table"}) in carriers of sickle cell disease (44.1), and higher in couples of AS/β-thalassemia trait, AA/AS, AA/SS, AS/S-β-thalassemia, and AS/SS than in controls (14.7). The carrier couples of sickle cell disease, AS/SS, and the couples with sickle cell disorders as a whole showed highly significant higher mortality under 10 years of age (p\<0.001) than the normal controls ([Table 2](#T2){ref-type="table"}). Similar results were noted for couples of AS/β-thalassemia trait and AS/S-β-thalassemia compared to controls. Similar results were obtained in carrier couples of sickle cell disorders per 1000 live-births for mortality \<10 years of age ([Table 3](#T3){ref-type="table"}).

Live Births {#sec2-6}
-----------

Couples of AA/SS genotypes had significantly (p\<0.02) lower number of live-births (70.0%), followed by AA/AS couples (p\<0.05) than the controls (91.9%) ([Table 2](#T2){ref-type="table"}). However, there was significantly higher number of live-births in couples of AA/AS (p\<0.05), and AA/SS (p\<0.001) than the controls. However, over all couples of sickle cell disorders did not show significantly higher number of live-births (\<0.10p\>0.05). There was significantly higher number of surviving offspring in couples of AA/AS, AA/SS, and sickle cell disorders (p\<0.001) than the controls. The sickle cell disease carriers (p\<0.01) and AS/SS couples (p\<0.05) also showed significantly higher number of surviving offspring than the controls ([Table 2](#T2){ref-type="table"}). Couples of AS/SS genotype had the lowest number of surviving children per 1000 live-births ([Table 3](#T3){ref-type="table"}).

Discussion {#sec1-4}
==========

Findings from this study show many practical aspects of couples with recessively inherited hemolytic disorders such as sickle cell disease in Central India. This study supports the contention that hereditary factors in the carrier couples, apart from concomitant nongenetic confounding factors, are responsible for the high reproductive loss in the form of abortions, still-births, neonatal and infant mortality, and mortality \<10 years of age in India ([Table 2](#T2){ref-type="table"}). This is an outcome of nonviable homozygosity of the recessively inherited genetic disorders such as sickle cell disease due to inbreeding that is inadvertently taking place in the vulnerable communities of the region that enhances morbidity and neonatal/infant mortality. This is the 1^st^ study carried out taking into consideration these causative aspects of high mortality in the state of Madhya Pradesh, India. These results are consistent with the similar findings reported from Odisha state\[[@ref8]\] in eastern coast of India.

These findings have also been supported by the high neonatal mortality rate which was 44 and 33 for Madhya Pradesh and India, respectively in the year 2010. Neonatal mortality was found almost doubled in carriers of sickle cell disease (34.3) than in controls (14.7) per 1000 live-births in the present study ([Table 3](#T3){ref-type="table"}). Similarly, the infant mortality rate of 62 was the highest for Madhya Pradesh as compared to 47 for India in the year 2011. This infant mortality rate has declined in Madhya Pradesh to 56 in the year 2012.\[[@ref14]\] The overall neonatal and infant mortality was recorded for carrier couples of sickle cell disorders to be 41.8 and 49.1, respectively per 1000 live-births against controls (14.7 for each category) in the present study.

There are very few studies available on the subject of fetal loss in India. Earlier in the state of Odisha, high neonatal (48.3) and infant (75.9) mortality per 1000 live-births was reported in carrier couples of sickle cell disease.\[[@ref8]\] The findings of the present study are not at variance from that of Odisha with respect to neonatal (41.8) and infant (49.1) mortality in Madhya Pradesh. This consistency of findings shows almost similar pattern of consanguinity or inbreeding in Odisha in the communities possessing recessively inherited genetic characters such as sickle cell disease,\[[@ref15]\] leading to increased homozygosity and reproductive loss, that is, abortions, still-births, neonatal and infant mortality or childhood mortality affecting the population fitness.

Looking at the overall scenario of reproductive loss and surviving offspring in different carrier couples of sickle cell disorders, the number of normal children born to carrier couples was lower (159/367; 43.3%) than the inflicted children (208/367; 56.7%), indicating the progressive increase of inflicted offspring in these families. This trend shows the lower fitness of the carrier couples or affected families, and, consequently, of the vulnerable population(s).

It has been observed that enhancement of the institutional delivery accompanied by quality public healthcare services provide added advantage to reproductive outcome, whereas, the widespread undernourishment and anemia among pregnant women lead to under-weight children. Moreover, lack of public health facilities to cope with specialized newborn care coupled with sickle cell disorders bring adverse reproductive outcomes. It was envisaged to bring awareness among these couples through genetic/marriage counseling about the deleterious genetic disorders and their causal effects on health. Their eradication is necessary because they are not curable but preventable through carrier detection, prenatal diagnosis and, education and genetic counseling. This has ample implications in those families, communities and tropical countries where sickle cell disease is widely prevalent and is a major cause of high morbidity and mortality. In order to bring the reduction/prevention and control of sickle cell disorders in affected families, all the referred and affected families were given genetic/marriage counseling to prevent the birth of an abnormal child in their families\[[@ref16], [@ref17]\] for the betterment of future generations.

Conclusions and Global Health Implications {#sec1-5}
==========================================

The increased production of inflicted trait and disease surviving offspring (56.7%) than the normal children (43.3%), leads to increased morbidity and mortality, and may be contributing towards increased neonatal/infant mortality in Madhya Pradesh. This is among the first attempts to report hereditary causes, apart from other concomitant non-genetic factors, responsible for the high neonatal/infant mortality (reproductive loss) in this population. Further, the progeny of sickle cell disease couples may be contributing to the disproportionate rate of neonatal/infant mortality in Madhya Pradesh. Genetic pre-marriage counseling is highly recommended in both affected and unaffected couples/families to ameliorate potential burdens to individuals and families.
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